Pain lasts longer for women than it does for men.Research has long indicated that men generally recover faster from pain and are less likely than women to develop chronic pain. Now scientists have a better idea why. 🔗 https://t.co/N5K5wuglpZ https://t.co/ZZVDOJT2Dp ...

Pain lasts longer for women than it does for men.Research has long indicated that men generally recover faster from pain and are less likely than women to develop chronic pain. Now scientists have a better idea why. 🔗 https://t.co/f1a52POJG7 https://t.co/34PqIVsQcZ ...

What causes chronic pain is often a mystery. But researchers have made a discovery that could lead to a more comfortable future for sufferers https://t.co/ioevUVtsAU ...

Regulatory Failures & Conflicts of Interest - The FDA failed in its oversight of opioids, contributing to the opioid epidemic [1] - Regulatory capture at the FDA is suspected, though unproven, with reviewers moving to Purdue Pharma after approving OxyContin for chronic pain based on a 14-day study [2] - Industry members have been removed from FDA advisory committees where possible to address potential conflicts of interest [3] - A conflict of interest exists if the team that approved a drug is responsible for evaluating its safety post-approval [6] Post-Market Drug Monitoring & Safety - The industry emphasizes the need for continuous monitoring of drugs and devices after approval [4] - The industry should not wait 19 years after a drug's approval to discover potentially deadly downstream effects, such as the alleged million deaths linked to OxyContin [5] - The industry advocates for using big data and epidemiology to monitor drugs for emerging safety signals [5] - The FDA previously had a system where bureaucrats could block safety epidemiology studies, which is being eliminated [5][6] Labeling & Scientific Integrity - The industry aims to ensure the accuracy and consistency of OxyContin and similar medications' labels with scientific evidence [3] - The industry is committed to preserving the scientific process in drug evaluation [4]